Results 261 to 270 of about 14,437,638 (295)
Some of the next articles are maybe not open access.
Immunopathogenesis of cutaneous T-cell lymphomas
Hematology/Oncology Clinics of North America, 2003The physiopathology of cutaneous T-cell lymphomas is poorly understood. Little is known about the factors that drive a mature T-cell clone to accumulate in the skin, despite the feedback mechanisms that normally control immune response. This article discusses the identification of tumor-specific antigens.
Martine, Bagot +2 more
openaire +2 more sources
Cutaneous T-cell lymphoma/leukemia
Current Treatment Options in Oncology, 2000Effective treatment for cutaneous T-cell lymphomas (CTCL) requires an accurate and specific diagnosis based on the clinical presentation combined with evaluation of the histopathology, immunophenotyping, and gene rearrangement studies. Careful clinical and pathologic evaluation in centers familiar with the diverse forms of CTCL is most valuable for ...
R S, Siegel, T M, Kuzel
openaire +2 more sources
Treatment of Cutaneous T-Cell Lymphoma
Dermatologic Clinics, 1985Intensive treatment of cutaneous T-cell lymphoma with modalities directed only at skin manifestations appears to cure up to 40 per cent of patients with early, limited skin involvement. For patients with widely disseminated skin lesions, the dermatologist often must choose a treatment regimen with both cutaneous and systemic effects in order to provide
E C, Vonderheid, B, Micaily
openaire +2 more sources
Overview of Cutaneous T-Cell Lymphomas
Hematology/Oncology Clinics of North America, 2019Non-Hodgkin's lymphoma (NHL) encompasses a diverse collection of systemic and primary cutaneous lymphomas. Cutaneous T-cell lymphomas (CTCLs) represent about 13% of all NHLs, which are further subdivided into a heterogeneous group with vastly different presentations and histologic features.
Cecilia A, Larocca, Nicole R, LeBoeuf
openaire +2 more sources
Vorinostat in cutaneous T-cell lymphoma
Drugs of Today, 2007Histone deacetylase inhibitors (HDAC-Is) are a novel class of small molecules being evaluated in clinical trials for a number of different malignancies. HDAC-Is are able to induce differentiation, apoptosis and/or cell cycle arrest of malignant cells selectively.
Madeleine, Duvic, Jenny, Vu
openaire +2 more sources
Rare Cutaneous T-Cell Lymphomas
Hematology/Oncology Clinics of North America, 2019Rare lymphoma includes the entities that occur in less than 1% of cases of all lymphomas. Although the percentage is low, there are more than eight lymphomas classified as rare lymphomas. This article describes clinical presentation, diagnosis, prognosis, and management of the most common rare lymphomas, including primary cutaneous γδ T-cell lymphoma ...
Fabiana, Damasco, Oleg E, Akilov
openaire +2 more sources
AJN, American Journal of Nursing, 1984
J L, Eddy, R, Selgas-Cordes, M, Curran
openaire +2 more sources
J L, Eddy, R, Selgas-Cordes, M, Curran
openaire +2 more sources
Cutaneous T cell lymphoma in children
Seminars in Cutaneous Medicine and Surgery, 1999Cutaneous T cell lymphoma (CTCL) is a term used to describe a heterogeneous group of lymphoproliferative disorders that involve the skin. Mycosis fungoides and Sézary syndrome are two forms of CTCL that arise in adults and are uncommon in children. Dermatologists frequently employ the term CTCL as a synonym for mycosis fungoides and Sézary syndrome ...
openaire +2 more sources
Cutaneous T-cell lymphoma of the vulva
American Journal of Obstetrics and Gynecology, 2020Pradip Dashraath +2 more
openaire +2 more sources